Denmark· DK-28106269219
Reblozyl
A luspatercept product containing luspatercept, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Luspatercept
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106269219
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B03XA06
Luspatercept, as other registers publish it.
- IcelandReblozylBristol-Myers Squibb Pharma EEIG*
- DenmarkReblozylBristol-Myers Squibb Pharma EEIG
- FinlandReblozylBristol-Myers Squibb Pharma EEIG
- United StatesReblozylCelgene Corporation
- FinlandReblozylBristol-Myers Squibb Pharma EEIG
- PolandReblozylBristol-Myers Squibb Pharma EEIG
- PolandReblozylBristol-Myers Squibb Pharma EEIG
- IcelandReblozylBristol-Myers Squibb Pharma EEIG*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac35bccf-63c4-47c0-8a8d-9f35514c5adb GET /v1/drugs/ac35bccf-63c4-47c0-8a8d-9f35514c5adb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til injektionsvæske, opløsning",
"source": "dkma",
"strength": "75 mg",
"auth_role": "MOD",
"dk_drugid": "28106269219",
"substance": "Luspatercept",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44007"
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.